Bexagliflozin

Drug Profile

Bexagliflozin

Alternative Names: Bexagliflozin L-proline; EGT-0001442; EGT-0001474; EGT-1442; THR-1442

Latest Information Update: 06 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Theracos
  • Class Antihyperglycaemics; Glucosides; Pyrans; Small molecules
  • Mechanism of Action Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Type 2 diabetes mellitus

Most Recent Events

  • 27 Sep 2017 Theracos initiates enrolment in a phase I trial for Type-2 diabetes mellitus (In volunteers) in USA (NCT03296800)
  • 17 Sep 2017 Theracos completes a phase I trial for Type-2 diabetes mellitus (In volunteers) (PO, Tablet) (NCT03197324)
  • 01 Sep 2017 Theracos plans a phase I trial for Type-2 diabetes mellitus(In volunteers) in (NCT03296800)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top